Mechanisms underlying food-drug interactions: Inhibition of intestinal metabolism and transport

Pharmacology and Therapeutics

Volumn 136, Issue 2, 2012, Pages 186-201

  Won, Christina S ^a   Oberlies, Nicholas H ^b   Paine, Mary F ^a  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

Author keywords

Food drug interaction; Grapefruit; Inhibition; Intestine; Metabolism; Transport

Indexed keywords

ALISKIREN; AMIODARONE; ATENOLOL; ATORVASTATIN; CELIPROLOL; CLOPIDOGREL; COLCHICINE; CORTISONE ACETATE; CYTOCHROME P450; DOCETAXEL; FEXOFENADINE; FLUOROURACIL; IMATINIB; LANSOPRAZOLE; MIDAZOLAM; MONTELUKAST; NIFEDIPINE; PARACETAMOL; PLANT MEDICINAL PRODUCT; TACROLIMUS; TOLVAPTAN;

ADDISON DISEASE; ALCOHOLIC BEVERAGE; APPLE JUICE; BEER; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG DISPOSITION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HUMAN; HYPERLIPIDEMIA; LOADING DRUG DOSE; ORANGE JUICE; POMEGRANATE JUICE; PRIORITY JOURNAL; RED WINE; REVIEW; SINGLE DRUG DOSE; TEA; TOMATO;

ANIMALS; ARYLSULFOTRANSFERASE; BEVERAGES; BIOLOGICAL TRANSPORT; CITRUS PARADISI; CYTOCHROME P-450 CYP3A; FOOD-DRUG INTERACTIONS; GLUCURONOSYLTRANSFERASE; HUMANS; INTESTINES;

EID: 84867328072     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2012.08.001     Document Type: Review

References (222)

1. A. Abdel-Rahman, N. Anyangwe, L. Carlacci, S. Casper, R.P. Danam, and E. Enongene The safety and regulation of natural products used as foods and food ingredients Toxicol Sci 123 2011 333 348
2. B.B. Aggarwal, and S. Shishodia Molecular targets of dietary agents for prevention and therapy of cancer Biochem Pharmacol 71 2006 1397 1421
3. S. Agosti, L. Casalino, G. Bertero, A. Barsotti, C. Brunelli, and S. Morelloni A dangerous fruit juice Am J Emerg Med 30 2012 e5 e8
4. Y. Allouche, A. Jiménez, M. Uceda, M.P. Aguilera, J.J. Gaforio, and G. Beltrán Triterpenic content and chemometric analysis of virgin olive oils from forty olive cultivars J Agric Food Chem 57 2009 3604 3610
5. H. Ando, S. Tsuruoka, H. Yanagihara, K. Sugimoto, M. Miyata, and Y. Yamazoe Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin Br J Clin Pharmacol 60 2005 494 497
6. M. Antonello, D. Montemurro, M. Bolognesi, M. Di Pascoli, A. Piva, and F. Grego Prevention of hypertension, cardiovascular damage and endothelial dysfunction with green tea extracts Am J Hypertens 20 2007 1321 1328
7. M. Asensi, A. Ortega, S. Mena, F. Feddi, and J.M. Estrela Natural polyphenols in cancer therapy Crit Rev Clin Lab Sci 48 2011 197 216
8. D.G. Bailey, G.K. Dresser, and J.R. Bend Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice Clin Pharmacol Ther 73 2003 529 537
9. D.G. Bailey Fruit juice inhibition of uptake transport: A new type of food-drug interaction Br J Clin Pharmacol 70 2010 645 655
10. L.Z. Benet The drug transporter-metabolism alliance: uncovering and defining the interplay Mol Pharm 6 2009 1631 1643
11. L.Z. Benet, C.L. Cummins, and C.Y. Wu Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data Curr Drug Metab 4 2003 393 398
12. M.B. Bolger, V. Lukacova, and W.S. Woltosz Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine AAPS J 11 2009 353 363
13. X. Boulenc, and O. Barberan Metabolic-based drug-drug interactions prediction, recent approaches for risk assessment along drug development Drug Metabol Drug Interact 26 2011 147 168
14. J.I. Boullata, and V.T. Armenti Handbook of Drug-Nutrient Interactions 2004 Humana New Jersey
15. F. Bouzom, K. Ball, N. Perdaems, and B. Walther Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs? Biopharm Drug Dispos 33 2012 55 71
16. S. Brill, C. Zimmermann, K. Berger, J. Drewe, and H. Gutmann In vitro interactions with repeated grapefruit juice administration - to peel or not to peel? Planta Med 75 2009 332 335
17. C. Brown, G. Taniguchi, and K. Yip The monoamine oxidase inhibitor-tyramine interaction J Clin Pharmacol 29 1989 529 532
18. A. Bruyère, X. Declèves, F. Bouzom, K. Ball, C. Marques, and X. Treton Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass Mol Pharm 7 2010 1596 1607
19. B. Burchell, C.H. Brierley, G. Monaghan, and D.J. Clark The structure and function of the UDP-glucuronosyltransferase gene family Adv Pharmacol 42 1998 335 338
20. B. Burchell, C.H. Brierley, and D. Rance Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation Life Sci 57 1995 1819 1831
21. L.N. Chan Drug-nutrient interaction in clinical nutrition Curr Opin Clin Nutr Metab Care 5 2002 327 332
22. J.L. Chang, J. Bigler, Y. Schwarz, S.S. Li, L. Li, and I.B. King UGT1A1 polymorphism is associated with serum bilirubin concentrations in a randomized, controlled, fruit and vegetable feeding trial J Nutr 137 2007 890 897
23. W.N. Charman, C.J. Porter, S. Mithani, and J.B. Dressman Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH J Pharm Sci 86 1997 269 282
24. S.T. Chen, J. Dou, R. Temple, R. Agarwal, K.M. Wu, and S. Walker New therapies from old medicines Nat Biotechnol 26 2008 1077 1083
25. J.Y. Chien, S. Friedrich, M.A. Heathman, D.P. de Alwis, and V. Sinha Pharmacokinetics/pharmacodynamics and the stages of drug development: role of modeling and simulation AAPS J 7 2005 E544 E559
26. H.H. Chow, I.A. Hakim, D.R. Vining, J.A. Crowell, C.A. Cordova, and W.M. Chew Effects of repeated green tea catechin administration on human cytochrome P450 activity Cancer Epidemiol Biomarkers Prev 15 2006 2473 2476
27. X. Chu, G. Philip, and R. Evers Comments on Mougey et al. (2009): absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics 19: 129-138 Pharmacogenet Genomics 22 2012 319 322
28. A.H. Chun, K. Erdman, Y.L. Chiu, B.L. Pilmer, R. Achari, and J.H. Cavanaugh Bioavailability of lansoprazole granules administered in juice or soft food compared with the intact capsule formulation Clin Ther 24 2002 1322 1331
29. T.A. Clarke, and L.A. Waskell The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin Drug Metab Dispos 31 2003 53 59
30. E.E.W. Cohen, C. Hartford, M.L. Maitland, K. Fox-Kay, P. Vogel, and K. Wu Grapefruit juice significantly increases bioavailability of weekly rapamycin (sirolimus) - evidence of safety and activity in a phase 1 study American Association for Cancer Research 100th Annual Meeting Abstract LB-135, Denver, CO, April 18-22 2009 2009 American Association for Cancer Research
31. C. Colalto Herbal interactions on absorption of drugs: mechanisms of action and clinical risk assessment Pharmacol Res 62 2010 207 227
32. M.W. Coughtrie, and L.E. Johnston Interactions between dietary chemicals and human sulfotransferases-molecular mechanisms and clinical significance Drug Metab Dispos 29 2001 522 528
33. J.M. Custodio, C.Y. Wu, and L.Z. Benet Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption Adv Drug Deliv Rev 60 2008 717 733
34. W.V. De Castro, S. Mertens-Talcott, A. Rubner, V. Butterweck, and H. Derendorf Variation of flavonoids and furanocoumarins in grapefruit juices: a potential source of variability in grapefruit juice-drug interaction studies J Agric Food Chem 54 2006 249 255
35. S.J. Dentali Successful botanical research requires botanical expertise Clin Pharmacol Ther 87 2010 149 151
36. H. Derendorf, and G. Hochhaus Handbook of Pharmacokinetic Pharmacodynamic Correlations (Pharmacology and Toxicology) 1995 CRC Press Florida
37. J.L. Donovan, K.D. Chavin, C.L. Devane, R.M. Taylor, J.S. Wang, and Y. Ruan Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers Drug Metab Dispos 32 2004 906 908
38. I.E. Dreosti Bioactive ingredients: antioxidants and polyphenols in tea Nutr Rev 54 1996 S51 S58
39. G.K. Dresser, D.G. Bailey, B.F. Leake, U.I. Schwarz, P.A. Dawson, and D.J. Freeman Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine Clin Pharmacol Ther 71 2002 11 20
40. K. Eagle Toxicological effects of red wine, orange juice, and other dietary SULT1A inhibitors via excess catecholamines Food Chem Toxicol 2012 10.1016/j.fct.2012.03.004
41. D.J. Edwards, M.E. Fitzsimmons, E.G. Schuetz, K. Yasuda, M.P. Ducharme, and L.H. Warbasse 6′,7′-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein Clin Pharmacol Ther 65 1999 237 244
42. H.J. Einolf Comparison of different approaches to predict metabolic drug-drug interactions Xenobiotica 37 2007 1257 1294
43. J.C. Espin, M.T. Garcia-Conesa, and F.A. Tomas-Barberan Nutraceuticals: facts and fiction Phytochemistry 68 2007 2986 3008
44. O.A. Fahmi, S. Hurst, D. Plowchalk, J. Cook, F. Guo, and K. Youdim Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction Drug Metab Dispos 37 2009 1658 1666
45. O.A. Fahmi, T.S. Maurer, M. Kish, E. Cardenas, S. Boldt, and D. Nettleton A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro Drug Metab Dispos 36 2008 1698 1708
46. J. Fan, S. Chen, E.C. Chow, and K.S. Pang PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism Curr Drug Metab 11 2010 743 761
47. D. Farkas, and D.J. Greenblatt Influence of fruit juices on drug disposition: discrepancies between in vitro and clinical studies Expert Opin Drug Metab Toxicol 4 2008 381 393
48. D. Farkas, L.E. Oleson, Y. Zhao, J.S. Harmatz, M.A. Zinny, and M.H. Court Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice J Clin Pharmacol 47 2007 286 294
49. F. Fenneteau, P. Poulin, and F. Nekka Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates J Pharm Sci 99 2010 486 514
50. M.B. Fisher, M.F. Paine, T.J. Strelevitz, and S.A. Wrighton The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism Drug Metab Rev 33 2001 273 297
51. D. Fleisher, C. Li, Y. Zhou, L.H. Pao, and A. Karim Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications Clin Pharmacokinet 36 1999 233 254
52. B.C. Foster, J.T. Arnason, A. Saleem, T.W. Tam, R. Liu, and J. Mao Comparative study of hops-containing products on human cytochrome P450-mediated metabolism J Agric Food Chem 59 2011 5159 5163
53. B.C. Foster, N. Kearns, J.T. Arnason, A. Saleem, C. Ogrodowczyk, and S. Desjardins Comparative study of hop-containing products on human cytochrome p450-mediated metabolism J Agric Food Chem 57 2009 5100 5105
54. H. Fuchikami, H. Satoh, M. Tsujimoto, S. Ohdo, H. Ohtani, and Y. Sawada Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B Drug Metab Dispos 34 2006 577 582
55. I. Fukazawa, N. Uchida, E. Uchida, and H. Yasuhara Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese Br J Clin Pharmacol 57 2004 448 455
56. A. Galetin, H. Burt, L. Gibbons, and J.B. Houston Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition Drug Metab Dispos 34 2006 166 175
57. A. Galetin, M. Gertz, and J.B. Houston Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions Expert Opin Drug Metab Toxicol 4 2008 909 922
58. A. Galetin, M. Gertz, and J.B. Houston Contribution of intestinal cytochrome P450-mediated metabolism to drug-drug inhibition and induction interactions Drug Metab Pharmacokinet 25 2010 28 47
59. A. Galetin, L.K. Hinton, H. Burt, R.S. Obach, and J.B. Houston Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs Curr Drug Metab 8 2007 685 693
60. A. Galetin, K. Ito, D. Hallifax, and J.B. Houston CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions J Pharmacol Exp Ther 314 2005 180 190
61. N. Gamage, A. Barnett, N. Hempel, R.G. Duggleby, K.F. Windmill, and J.L. Martin Human sulfotransferases and their role in chemical metabolism Toxicol Sci 90 2006 5 22
62. D. Genser Food and drug interaction: consequences for the nutrition/health status Ann Nutr Metab 52 Suppl. 1 2008 29 32
63. C. Gerhauser Cancer chemopreventive potential of apples, apple juice, and apple components Planta Med 74 2008 1608 1624
64. M. Gertz, A. Harrison, J.B. Houston, and A. Galetin Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data Drug Metab Dispos 38 2010 1147 1158
65. M. Gertz, J.B. Houston, and A. Galetin Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction Drug Metab Dispos 39 2011 1633 1642
66. M.A. Gibbs, and N.A. Hosea Factors affecting the clinical development of cytochrome p450 CYP3A substrates Clin Pharmacokinet 42 2003 969 984
67. H. Glaeser, D.G. Bailey, G.K. Dresser, J.C. Gregor, U.I. Schwarz, and J.S. McGrath Intestinal drug transporter expression and the impact of grapefruit juice in humans Clin Pharmacol Ther 81 2007 362 370
68. J.K. Glisson, and L.A. Walker How physicians should evaluate dietary supplements Am J Med 123 2010 577 582
69. J.V. Gobburu, and P.J. Marroum Utilisation of pharmacokinetic- pharmacodynamic modelling and simulation in regulatory decision-making Clin Pharmacokinet 40 2001 883 892
70. D.J. Greenblatt Analysis of drug interactions involving fruit beverages and organic anion-transporting polypeptides J Clin Pharmacol 49 2009 1403 1407
71. J. Gruenwald Novel botanical ingredients for beverages Clin Dermatol 27 2009 210 216
72. E.J. Guest, K. Rowland-Yeo, A. Rostami-Hodjegan, G.T. Tucker, J.B. Houston, and A. Galetin Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models Br J Clin Pharmacol 71 2011 72 87
73. J.M. Guilford, and J.M. Pezzuto Wine and health: a review Am J Enol Vitic 62 2011 471 486
74. A. Guinda, M. Rada, T. Delgado, P. Gutiérrez-Adánez, and J.M. Castellano Pentacyclic triterpenoids from olive fruit and leaf J Agric Food Chem 58 2010 9685 9691
75. L.Q. Guo, K. Fukuda, T. Ohta, and Y. Yamazoe Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity Drug Metab Dispos 28 2000 766 771
76. B.J. Gurley Clinical pharmacology and dietary supplements: an evolving relationship Clin Pharmacol Ther 87 2010 235 238
77. B. Hagenbuch, and C. Gui Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family Xenobiotica 38 2008 778 801
78. M.J. Hanley, P. Cancalon, W.W. Widmer, and D.J. Greenblatt The effect of grapefruit juice on drug disposition Expert Opin Drug Metab Toxicol 7 2011 267 286
79. D.E. Harbourt, J.K. Fallon, S. Ito, T. Baba, J.K. Ritter, and G.L. Glish Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry Anal Chem 84 2012 98 105
80. R.M. Harris, and R.H. Waring Sulfotransferase inhibition: potential impact of diet and environmental chemicals on steroid metabolism and drug detoxification Curr Drug Metab 9 2008 269 275
81. X. He, and R.H. Liu Cranberry phytochemicals: isolation, structure elucidation, and their antiproliferative and antioxidant activities J Agric Food Chem 54 2006 7069 7074
82. M.C. Henderson, C.L. Miranda, J.F. Stevens, M.L. Deinzer, and D.R. Buhler In vitro inhibition of human P450 enzymes by prenylated flavonoids from hops, Humulus lupulus Xenobiotica 30 2000 235 251
83. M. Hidaka, M. Okumura, K. Fujita, T. Ogikubo, K. Yamasaki, and T. Iwakiri Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats Drug Metab Dispos 33 2005 644 648
84. A. Hisaka, Y. Ohno, T. Yamamoto, and H. Suzuki Theoretical considerations on quantitative prediction of drug-drug interactions Drug Metab Pharmacokinet 25 2010 48 61
85. P.C. Ho, D.J. Saville, P.F. Coville, and S. Wanwimolruk Content of CYP3A4 inhibitors, naringin, naringenin and bergapten in grapefruit and grapefruit juice products Pharm Acta Helv 74 2000 379 385
86. A.M. Holbrook, J.A. Pereira, R. Labiris, H. McDonald, J.D. Douketis, and M. Crowther Systematic overview of warfarin and its drug and food interactions Arch Intern Med 165 2005 1095 1106
87. N. Holford, S.C. Ma, and B.A. Ploeger Clinical trial simulation: a review Clin Pharmacol Ther 88 2010 166 182
88. J.B. Houston, and A. Galetin Methods for predicting in vivo pharmacokinetics using data from in vitro assays Curr Drug Metab 9 2008 940 951
89. S.M. Huang, J.M. Strong, L. Zhang, K.S. Reynolds, S. Nallani, and R. Temple New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process J Clin Pharmacol 48 2008 662 670
90. S.M. Huang, H. Zhao, J.I. Lee, K. Reynolds, L. Zhang, and R. Temple Therapeutic protein-drug interactions and implications for drug development Clin Pharmacol Ther 87 2010 497 503
91. K. Huvaere, M.L. Andersen, K. Olsen, L.H. Skibsted, A. Heyerick, and D. De Keukeleire Radicaloid-type oxidative decomposition of beer bittering agents revealed Chemistry 9 2003 4693 4699
92. I. Ieiri, Y. Doi, K. Maeda, T. Sasaki, M. Kimura, and T. Hirota Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose J Clin Pharmacol 2011 10.1177/0091270011408612
93. J. Imanaga, T. Kotegawa, H. Imai, K. Tsutsumi, T. Yoshizato, and T. Ohyama The effects of the SLCO2B1 c.1457C>T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans Pharmacogenet Genomics 21 2011 84 93
94. G.R. Jang, and R.Z. Harris Drug interactions involving ethanol and alcoholic beverages Expert Opin Drug Metab Toxicol 3 2007 719 731
95. H. Jeon, K.S. Lim, K. Ohashi, T. Kotegawa, I. Ieiri, and J.Y. Cho Apple juice greatly reduces plasma concentrations of atenolol 2012 American Society for Clinical Pharmacology and Therapeutics Annual Meeting Abstract PII-78, National Harbor, MD, March 12-17, 2012 2012 American Society for Clinical Pharmacology and Therapeutics
96. H. Jung, A.A. Peregrina, J.M. Rodriquez, and R. Moreno-Esparza The influence of coffee with milk and tea with milk on the bioavailability of tetracycline Biopharm Drug Dispos 18 1997 459 463
97. S.M. Kakar, M.F. Paine, P.W. Stewart, and P.B. Watkins 6′7′-Dihydroxybergamottin contributes to the grapefruit juice effect Clin Pharmacol Ther 75 2004 569 579
98. N.M. Kaplan, and B.F. Palmer Nutritional and health benefits of beer Am J Med Sci 320 2000 320 326
99. Y. Kato, T. Miyazaki, T. Kano, T. Sugiura, Y. Kubo, and A. Tsuji Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol J Pharm Sci 98 2009 2529 2539
100. M. Kazui, Y. Nishiya, T. Ishizuka, K. Hagihara, N.A. Farid, and O. Okazaki Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite Drug Metab Dispos 38 2010 92 99
101. R.B. Kim Organic anion-transporting polypeptide (OATP) transporter family and drug disposition Eur J Clin Invest 33 Suppl. 2 2003 1 5
102. E. Kim, A. Sy-Cordero, T.N. Graf, S.J. Brantley, M.F. Paine, and N.H. Oberlies Isolation and identification of intestinal CYP3A inhibitors from cranberry (Vaccinium macrocarpon) using human intestinal microsomes Planta Med 77 2011 265 270
103. S. Kimura, S. Kako, H. Wada, K. Sakamoto, M. Ashizawa, and M. Sato Can grapefruit juice decrease the cost of imatinib for the treatment of chronic myelogenous leukemia? Leuk Res 35 2011 e11 e12
104. C.D. Klaassen, and J.W. Boles Sulfation and sulfotransferases 5: the importance of 3′-phosphoadenosine 5′-phosphosulfate (PAPS) in the regulation of sulfation FASEB J 11 1997 404 418
105. M. Krenz, and R.J. Korthuis Moderate ethanol ingestion and cardiovascular protection: from epidemiologic associations to cellular mechanisms J Mol Cell Cardiol 52 2012 93 104
106. H.H. Kupferschmidt, H.R. Ha, W.H. Ziegler, P.J. Meier, and S. Krahenbuhl Interaction between grapefruit juice and midazolam in humans Clin Pharmacol Ther 58 1995 20 28
107. I. Laverdière, P. Caron, M. Harvey, É. Lévesque, and C. Guillemette In vitro investigation of human UDP-glucuronosyltransferase isoforms responsible for tacrolimus glucuronidation: predominant contribution of UGT1A4 Drug Metab Dispos 39 2011 1127 1130
108. C. Le Tiec, A. Barrail, C. Goujard, and A.M. Taburet Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir Clin Pharmacokinet 44 2005 1035 1050
109. K.A. Lentz Current methods for predicting human food effect AAPS J 10 2008 282 288
110. Z. Li, N.N. Vachharajani, and R. Krishna On the assessment of effects of food on the pharmacokinetics of drugs in early development Biopharm Drug Dispos 23 2002 165 171
111. B.M. Liederer, and R.T. Borchardt Enzymes involved in the bioconversion of ester-based prodrugs J Pharm Sci 95 2006 1177 1195
112. J.J. Lilja, J.T. Backman, J. Laitila, H. Luurila, and P.J. Neuvonen Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol Clin Pharmacol Ther 73 2003 192 198
113. J.J. Lilja, J.T. Backman, and P.J. Neuvonen Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam-probes of CYP2C9, CYP1A2, and CYP3A4 Clin Pharmacol Ther 81 2007 833 839
114. J.J. Lilja, L. Juntti-Patinen, and P.J. Neuvonen Orange juice substantially reduces the bioavailability of the beta-adrenergic-blocking agent celiprolol Clin Pharmacol Ther 75 2004 184 190
115. J.J. Lilja, K.T. Kivistö, J.T. Backman, and P.J. Neuvonen Effect of grapefruit juice dose on grapefruit juice-triazolam interaction: repeated consumption prolongs triazolam half-life Eur J Clin Pharmacol 56 2000 411 415
116. J.J. Lilja, K.T. Kivistö, and P.J. Neuvonen Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin Clin Pharmacol Ther 66 1999 118 127
117. J.J. Lilja, M. Neuvonen, and P.J. Neuvonen Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin Br J Clin Pharmacol 58 2004 56 60
118. J.J. Lilja, K. Raaska, and P.J. Neuvonen Effects of orange juice on the pharmacokinetics of atenolol Eur J Clin Pharmacol 61 2005 337 340
119. J.H. Lin, and A.Y. Lu Interindividual variability in inhibition and induction of cytochrome P450 enzymes Annu Rev Pharmacol Toxicol 41 2001 535 567
120. C. Liu, Y.F. Shang, X.F. Zhang, X.G. Zhang, B. Wang, and Z. Wu Co-administration of grapefruit juice increases bioavailability of tacrolimus in liver transplant patients: a prospective study Eur J Clin Pharmacol 65 2009 881 885
121. R. Lourenço Enteral feeding: drug/nutrient interaction Clin Nutr 20 2001 187 193
122. K.S. Lown, D.G. Bailey, R.J. Fontana, S.K. Janardan, C.H. Adair, and L.A. Fortlage Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression J Clin Invest 99 1997 2545 2553
123. T. Maeda, K. Takahashi, N. Ohtsu, T. Oguma, T. Ohnishi, and R. Atsumi Identification of influx transporter for the quinolone antibacterial agent levofloxacin Mol Pharm 4 2007 85 94
124. S. Malhotra, D.G. Bailey, M.F. Paine, and P.B. Watkins Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins Clin Pharmacol Ther 69 2001 14 23
125. K. Mandery, K. Bujok, I. Schmidt, M. Keiser, W. Siegmund, and B. Balk Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1 Biochem Pharmacol 80 2010 1746 1753
126. J.S. Markowitz, L.L. von Moltke, and J.L. Donovan Predicting interactions between conventional medications and botanical products on the basis of in vitro investigations Mol Nutr Food Res 52 2008 747 754
127. B.J. McCabe Prevention of food-drug interactions with special emphasis on older adults Curr Opin Clin Nutr Metab Care 7 2004 21 26
128. B.J. McCabe, E.H. Frankel, and J.J. Wolfe Handbook of Food-Drug Interactions 2003 CRC Press Florida
129. K.A. Meckling Nutrient-Drug Interactions 2007 CRC Press Florida
130. R. Meech, and P.I. Mackenzie Structure and function of uridine diphosphate glucuronosyltransferases Clin Exp Pharmacol Physiol 24 1997 907 915
131. Y. Meier, J.J. Eloranta, J. Darimont, M.G. Ismair, C. Hiller, and M. Fried Regional distribution of solute carrier mRNA expression along the human intestinal tract Drug Metab Dispos 35 2007 590 594
132. S.U. Mertens-Talcott, I. Zadezensky, W.V. De Castro, H. Derendorf, and V. Butterweck Grapefruit-drug interactions: can interactions with drugs be avoided? J Clin Pharmacol 46 2006 1390 1416
133. P. Methlie, E.E. Husebye, S. Hustad, E.A. Lien, and K. Lovås Grapefruit juice and licorice increase cortisol availability in patients with Addison's disease Eur J Endocrinol 165 2011 761 769
134. R. Miller, W. Ewy, B.W. Corrigan, D. Ouellet, D. Hermann, and K.G. Kowalski How modeling and simulation have enhanced decision making in new drug development J Pharmacokinet Pharmacodyn 32 2005 185 197
135. X. Ming, B.M. Knight, and D.R. Thakker Vectorial transport of fexofenadine across Caco-2 cells: involvement of apical uptake and basolateral efflux transporters Mol Pharm 8 2011 1677 1686
136. S. Misaka, R. Nakamura, S. Uchida, K. Takeuchi, N. Takahashi, and N. Inui Effect of 2 weeks' consumption of pomegranate juice on the pharmacokinetics of a single dose of midazolam: an open-label, randomized, single-center, 2-period crossover study in healthy Japanese volunteers Clin Ther 33 2011 246 252
137. M.E. Mohamed, and R.F. Frye Inhibitory effects of commonly used herbal extracts on UDP-glucuronosyltransferase 1A4, 1A6, and 1A9 enzyme activities Drug Metab Dispos 39 2011 1522 1528
138. E.B. Mougey, H. Feng, M. Castro, C.G. Irvin, and J.J. Lima Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response Pharmacogenet Genomics 19 2009 129 138
139. E.B. Mougey, J.E. Lang, X. Wen, and J.J. Lima Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast J Clin Pharmacol 51 2011 751 760
140. S.J. Mouly, C. Matheny, M.F. Paine, G. Smith, J. Lamba, and V. Lamba Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5 Clin Pharmacol Ther 78 2005 605 618
141. S.L. Navarro, Y. Chen, L. Li, S.S. Li, J.L. Chang, and Y. Schwarz UGT1A6 and UGT2B15 polymorphisms and acetaminophen conjugation in response to a randomized, controlled diet of select fruits and vegetables Drug Metab Dispos 39 2011 1650 1657
142. S.L. Navarro, S. Peterson, C. Chen, K.W. Makar, Y. Schwarz, and I.B. King Cruciferous vegetable feeding alters UGT1A1 activity: diet- and genotype-dependent changes in serum bilirubin in a controlled feeding trial Cancer Prev Res (Phila) 2 2009 345 352
143. A.L. Neuhofel, J.H. Wilton, J.M. Victory, L.G. Hejmanowsk, and G.W. Amsden Lack of bioequivalence of ciprofloxacin when administered with calcium-fortified orange juice: a new twist on an old interaction J Clin Pharmacol 42 2002 461 466
144. N. Ngo, Z. Yan, T.N. Graf, D.R. Carrizosa, A.D. Kashuba, and E.C. Dees Identification of a cranberry juice product that inhibits enteric CYP3A-mediated first-pass metabolism in humans Drug Metab Dispos 37 2009 514 522
145. H. Nishimuta, H. Ohtani, M. Tsujimoto, K. Ogura, A. Hiratsuka, and Y. Sawada Inhibitory effects of various beverages on human recombinant sulfotransferase isoforms SULT1A1 and SULT1A3 Biopharm Drug Dispos 28 2007 491 500
146. H. Nishimuta, M. Tsujimoto, K. Ogura, A. Hiratsuka, H. Ohtani, and Y. Sawada Inhibitory effects of various beverages on ritodrine sulfation by recombinant human sulfotransferase isoforms SULT1A1 and SULT1A3 Pharm Res 22 2005 1406 1410
147. R.S. Obach Predicting drug-drug interactions from in vitro drug metabolism data: challenges and recent advances Curr Opin Drug Discov Devel 12 2009 81 89
148. R.S. Obach, R.L. Walsky, and K. Venkatakrishnan Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions Drug Metab Dispos 35 2007 246 255
149. R.S. Obach, R.L. Walsky, K. Venkatakrishnan, E.A. Gaman, J.B. Houston, and L.M. Tremaine The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions J Pharmacol Exp Ther 316 2006 336 348
150. R.S. Obach, R.L. Walsky, K. Venkatakrishnan, J.B. Houston, and L.M. Tremaine In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach Clin Pharmacol Ther 78 2005 582 592
151. M.F. Paine, A.B. Criss, and P.B. Watkins Two major grapefruit juice components differ in intestinal CYP3A4 inhibition kinetic and binding properties Drug Metab Dispos 32 2004 1146 1153
152. M.F. Paine, A.B. Criss, and P.B. Watkins Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition J Pharmacol Exp Ther 312 2005 1151 1160
153. M.F. Paine, H.L. Hart, S.S. Ludington, R.L. Haining, A.E. Rettie, and D.C. Zeldin The human intestinal cytochrome P450 pie Drug Metab Dispos 34 2006 880 886
154. M.F. Paine, and N.H. Oberlies Clinical relevance of the small intestine as an organ of drug elimination: drug-fruit juice interactions Expert Opin Drug Metab Toxicol 3 2007 67 80
155. K.S. Pang, and M.R. Durk Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion J Pharmacokinet Pharmacodyn 37 2010 591 615
156. N. Parrott, V. Lukacova, G. Fraczkiewicz, and M.B. Bolger Predicting pharmacokinetics of drugs using physiologically based modeling-application to food effects AAPS J 11 2009 45 53
157. H.H. Parving, B.M. Brenner, J.J. McMurray, D. de Zeeuw, S.M. Haffner, and S.D. Solomon Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design Nephrol Dial Transplant 24 2009 1663 1671
158. A.A. Patchett The chemistry of enalapril Br J Clin Pharmacol 18 1984 201S 207S
159. M.A. Peltoniemi, T.I. Saari, N.M. Hagelberg, K. Laine, P.J. Neuvonen, and K.T. Olkkola S-ketamine concentrations are greatly increased by grapefruit juice Eur J Clin Pharmacol 2012 10.1007/s00228-012-1214-9
160. S.R. Penzak, E.P. Acosta, M. Turner, D.J. Edwards, Y.Y. Hon, and H.D. Desai Effect of Seville orange juice and grapefruit juice on indinavir pharmacokinetics J Clin Pharmacol 42 2002 1165 1170
161. S.A. Peters Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles Clin Pharmacokinet 47 2008 245 259
162. S. Peterson, J. Bigler, N.K. Horner, J.D. Potter, and J.W. Lampe Cruciferae interact with the UGT1A1*28 polymorphism to determine serum bilirubin levels in humans J Nutr 135 2005 1051 1055
163. B. Piver, F. Berthou, Y. Dreano, and D. Lucas Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components Toxicol Lett 125 2001 83 91
164. G.L. Plosker, and L.J. Scott Saquinavir: a review of its use in boosted regimens for treating HIV infection Drugs 63 2003 1299 1324
165. R.E. Polk Drug-drug interactions with ciprofloxacin and other fluoroquinolones Am J Med 87 5A 1989 76S 81S
166. P. Poulin, R.D. Jones, H.M. Jones, C.R. Gibson, M. Rowland, and J.Y. Chien PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach J Pharm Sci 2011 10.1002/jps.22550
167. R. Pulido, M. Hernández-García, and F. Saura-Calixto Contribution of beverages to the intake of lipophilic and hydrophilic antioxidants in the Spanish diet Eur J Clin Nutr 57 2003 1275 1282
168. J. Qiao, C. Gu, W. Shang, J. Du, W. Yin, and M. Zhu Effect of green tea on pharmacokinetics of 5-fluorouracil in rats and pharmacodynamics in human cell lines in vitro Food Chem Toxicol 49 2011 1410 1415
169. A. Radominska-Pandya, P.J. Czernik, J.M. Little, E. Battaglia, and P.I. Mackenzie Structural and functional studies of UDP-glucuronosyltransferases Drug Metab Rev 31 1999 817 899
170. P.R. Ravi, R. Vats, R. Thakur, S. Srivani, and N. Aditya Effect of grapefruit juice and ritonavir on pharmacokinetics of lopinavir in Wistar rats Phytother Res 2012 10.1002/ptr.4593
171. S. Rebello, S. Zhao, S. Hariry, M. Dahlke, N. Alexander, and A. Vapurcuyan Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects Eur J Clin Pharmacol 2011 10.1007/s00228-011-1167-4
172. P. Reddy, D. Ellington, Y. Zhu, I. Zdrojewski, S.J. Parent, and J.S. Harmatz Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily Br J Clin Pharmacol 72 2011 434 441
173. J.K. Ritter Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics Expert Opin Drug Metab Toxicol 3 2007 93 107
174. L. Rodríguez-Fragoso, J.L. Martínez-Arismendi, D. Orozco-Bustos, J. Reyes-Esparza, E. Torres, and S.W. Burchiel Potential risks resulting from fruit/vegetable-drug interactions: effects on drug-metabolizing enzymes and drug transporters J Food Sci 76 2011 R112 R124
175. S.A. Ross, D.S. Ziska, K. Zhao, and M.A. ElSohly Variance of common flavonoids by brand of grapefruit juice Fitoterapia 71 2000 154 161
176. M. Roth, J.J. Araya, B.N. Timmermann, and B. Hagenbuch Isolation of modulators of the liver specific organic anion-transporting polypeptides (OATPs) 1B1 and 1B3 from Rollinia emarginata Schlecht (Annonaceae) J Pharmacol Exp Ther 339 2011 624 632
177. M. Roth, B.N. Timmermann, and B. Hagenbuch Interactions of green tea catechins with organic anion-transporting polypeptides Drug Metab Dispos 39 2011 920 926
178. M. Rowland, C. Peck, and G. Tucker Physiologically-based pharmacokinetics in drug development and regulatory science Annu Rev Pharmacol Toxicol 10 2011 45 73
179. R. Sabra Topics in clinical pharmacology: lovastatin Am J Med Sci 296 1988 426 428
180. Y. Sai, Y. Kaneko, S. Ito, K. Mitsuoka, Y. Kato, and I. Tamai Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells Drug Metab Dispos 34 2006 1423 1431
181. M. Saito, M. Hirata-Koizumi, M. Matsumoto, T. Urano, and R. Hasegawa Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies Drug Saf 28 2005 677 694
182. S. Sang, J.D. Lambert, C.T. Ho, and C.S. Yang The chemistry and biotransformation of tea constituents Pharmacol Res 64 2011 87 99
183. C.A. Santos, and J.I. Boullata An approach to evaluating drug-nutrient interactions Pharmacotherapy 25 2005 1789 1800
184. M.R. Saracino, J. Bigler, Y. Schwarz, J.L. Chang, S. Li, and L. Li Citrus fruit intake is associated with lower serum bilirubin concentration among women with the UGT1A1*28 polymorphism J Nutr 139 2009 555 560
185. P. Schmiedlin-Ren, D.J. Edwards, M.E. Fitzsimmons, K. He, K.S. Lown, and P.M. Woster Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins Drug Metab Dispos 25 1997 1228 1233
186. K. Seden, L. Dickinson, S. Khoo, and D. Back Grapefruit-drug interactions Drugs 70 2010 2373 2407
187. T.H. Self, C.R. Chrisman, A.M. Baciewicz, and M.S. Bronze Isoniazid drug and food interactions Am J Med Sci 317 1999 304 311
188. C.E. Shardlow, G.T. Generaux, C.C. MacLauchlin, N. Pons, K.W. Skordos, and J.C. Bloomer Utilizing drug-drug interaction prediction tools during drug development: enhanced decision making based on clinical risk Drug Metab Dispos 39 2011 2076 2084
189. D.D. Shen, K.L. Kunze, and K.E. Thummel Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction Adv Drug Deliv Rev 27 1997 99 127
190. S.E. Shoaf, S. Mallikaarjun, and P. Bricmont Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist, in healthy subjects Eur J Clin Pharmacol 68 2012 207 211
191. B.N. Singh Effects of food on clinical pharmacokinetics Clin Pharmacokinet 37 1999 213 255
192. T.J. Smillie, and I.A. Khan A comprehensive approach to identifying and authenticating botanical products Clin Pharmacol Ther 87 2010 175 186
193. M.B. Stargrove, J. Treasure, and D.L. McKee Herb, Nutrient, and Drug Interactions: Clinical Implications and Therapeutic Strategies 2008 Mosby Elsevier Missouri
194. L. Stupans, H.W. Tan, A. Kirlich, K. Tuck, P. Hayball, and M. Murray Inhibition of CYP3A-mediated oxidation in human hepatic microsomes by the dietary derived complex phenol, gallic acid J Pharm Pharmacol 54 2002 269 275
195. K. Sunaga, K. Ohkawa, K. Nakamura, A. Ohkubo, S. Harada, and T. Tsuda Mechanism-based inhibition of recombinant human cytochrome P450 3A4 by tomato juice extract Biol Pharm Bull 35 2012 329 334
196. T. Tachibana, M. Kato, and Y. Sugiyama Prediction of nonlinear intestinal absorption of CYP3A4 and P-glycoprotein substrates from their in vitro Km values Pharm Res 29 2012 651 668
197. T. Tachibana, M. Kato, J. Takano, and Y. Sugiyama Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein Curr Drug Metab 11 2010 762 777
198. T. Tapaninen, P.J. Neuvonen, and M. Niemi Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren Clin Pharmacol Ther 88 2010 339 342
199. T. Tapaninen, P.J. Neuvonen, and M. Niemi Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren Br J Clin Pharmacol 71 2011 718 726
200. T. Tateishi, P. Soucek, Y. Caraco, F.P. Guengerich, and A.J. Wood Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation Biochem Pharmacol 53 1997 111 116
201. K.E. Thummel, and G.R. Wilkinson In vitro and in vivo drug interactions involving human CYP3A Annu Rev Pharmacol Toxicol 38 1998 389 430
202. C.S. Tidball The nature of the intestinal epithelial barrier Am J Dig Dis 16 1971 745 767
203. R. Tzulker, I. Glazer, I. Bar-Ilan, D. Holland, M. Aviram, and R. Amir Antioxidant activity, polyphenol content, and related compounds in different fruit juices and homogenates prepared from 29 different pomegranate accessions J Agric Food Chem 55 2007 9559 9570
204. Y. Uesawa, M. Abe, E. Fukuda, M. Baba, Y. Okada, and K. Mohri Construction of a model to estimate the CYP3A inhibitory effect of grapefruit juice Pharmazie 66 2011 525 528
205. Y. Uesawa, and K. Mohri Effects of cranberry juice on nifedipine pharmacokinetics in rats J Pharm Pharmacol 58 2006 1067 1072
206. B. Valenzuela, J. Rebollo, T. Pérez, A. Brugarolas, and J.J. Pérez-Ruixo Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report Br J Clin Pharmacol 72 2011 978 981
207. H. van de Waterbeemd, and E. Gifford ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov 2 2003 192 204
208. E.M. van der Logt, H.M. Roelofs, F.M. Nagengast, and W.H. Peters Induction of rat hepatic and intestinal UDP-glucuronosyltransferases by naturally occurring dietary anticarcinogens Carcinogenesis 24 2003 1651 1656
209. J.A. Vinson, M. Mandarano, M. Hirst, J.R. Trevithick, and P. Bose Phenol antioxidant quantity and quality in foods: beers and the effect of two types of beer on an animal model of atherosclerosis J Agric Food Chem 51 2003 5528 5533
210. J.A. Vinson, K. Teufel, and N. Wu Green and black teas inhibit atherosclerosis by lipid, antioxidant, and fibrinolytic mechanisms J Agric Food Chem 52 2004 3661 3665
211. G. Vischini, P. Niscola, A. Stefoni, and F. Farneti Increased plasma levels of tacrolimus after ingestion of green tea Am J Kidney Dis 58 2011 329
212. F. Visioli, C.A. De La Lastra, C. Andres-Lacueva, M. Aviram, C. Calhau, and A. Cassano Polyphenols and human health: a prospectus Crit Rev Food Sci Nutr 51 2011 524 546
213. A.W. Wallace, J.M. Victory, and G.W. Amsden Lack of bioequivalence when levofloxacin and calcium-fortified orange juice are coadministered to healthy volunteers J Clin Pharmacol 43 2003 539 544
214. S. Wanwimolruk, and P.V. Marquez Variations in content of active ingredients causing drug interactions in grapefruit juice products sold in California Drug Metabol Drug Interact 21 2006 233 243
215. S. Wason, J. DiGiacinto, and M.W. Davis Consumption of grapefruit or Seville orange juice does not affect the pharmacokinetics of colchicine American Society for Clinical Pharmacology and Therapeutics Annual Meeting Abstract PI-77, Dallas, TX, March 2-5, 2011 2011 American Society for Clinical Pharmacology and Therapeutics
216. I. Wolinsky, and L. Williams Nutrition in Pharmacy Practice 2002 American Pharmaceutical Association Washington, DC
217. C.S. Won, N.H. Oberlies, and M.F. Paine Influence of dietary substances on intestinal drug metabolism and transport Curr Drug Metab 11 2010 778 792
218. C.P. Wu, S. Ohnuma, and S.V. Ambudkar Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy Curr Pharm Biotechnol 12 2011 609 620
219. J. Yang, M. Jamei, K.R. Yeo, G.T. Tucker, and A. Rostami-Hodjegan Prediction of intestinal first-pass drug metabolism Curr Drug Metab 8 2007 676 684
220. K.A. Youdim, A. Zayed, M. Dickins, A. Phipps, M. Griffiths, and A. Darekar Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction Br J Clin Pharmacol 65 2008 680 692
221. N.T. Zaveri Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications Life Sci 78 2006 2073 2080
222. P. Zhao, L. Zhang, J.A. Grillo, Q. Liu, J.M. Bullock, and Y.J. Moon Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review Clin Pharmacol Ther 89 2011 259 267